|本期目录/Table of Contents|

[1]邵明永,丁庆莉,高 纯,等.CA125和CA153联合检测对乳腺癌的诊治价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):433-435.[doi:10.3969/j.issn.1672-271X.2013.05.001]
　SHAO Ming-yong,DING Qing-li,GAO Chun,et al.Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(05):433-435.[doi:10.3969/j.issn.1672-271X.2013.05.001]
点击复制

CA125和CA153联合检测对乳腺癌的诊治价值()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第15卷
期数:
2013年05期
页码:
433-435
栏目:
出版日期:
2013-10-20

文章信息/Info

Title:
Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer
作者:
邵明永1; 丁庆莉2; 高 纯3; 王峻峰1; 任传路2
１.215007江苏苏州,解放军10１医院１００临床部普外科，2.检验科；3.215006江苏苏州，苏州大学附属第一医院检验科
Author(s):
SHAO Ming-yong1; DING Qing-li2; GAO Chun3; WANG Jun-feng1; REN Chuan-lu2
1.Department of General Surgery，2.Department of Laboratory，100 Clinical Branch of 101 Hospital,PLA,Suzhou,Jiangsu 215007,China；3.Department of Laboratory of First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215006,China
关键词:
电化学发光法; 乳腺癌; 肿瘤标志物; 联合检测
Keywords:
electrochemoluminescent immunoassay;  breast cancer;  tumor marker;  combined detection
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2013.05.001
文献标志码:
A
摘要:
目的 探讨肿瘤标志物CA125和CA153对乳腺癌诊断和疗效监测的价值。方法 采用电化学发光法对乳腺癌170例、乳腺良性疾病102例及健康体检者153例的血清进行CA125和CA153联合检测，并对乳腺癌80例术后第3天、1周、2周和1个月的CA125和CA153的水平进行监测。应用ROC曲线对各指标进行分析。结果 乳腺癌组CA153、CA125均明显高于乳腺良性疾病组与正常对照组（P<0.05）；CA153、CA125两项联合检测，其灵敏度为79.41%、准确度为87.53%、阴性预测值为87.13%，与单项指标比较差异均有统计学意义（P<0.05）。CA153、CA125两项肿瘤标志物单独检测时，CA153的ＲＯＣ曲线下面积（AUC）为0.823较CA125大；两项联合指标的AUC达0.876，大于各单项肿瘤标志物（P<0.05）。结论 CA153、CA125是乳腺癌的肿瘤相关性标志物，CA153对于乳腺癌的诊断价值更大。两项指标联合检测优于单一的肿瘤标志物检测，可提高诊断乳腺癌的正确性。CA153、CA125亦可用于乳腺癌患者术后疗效的观察。
Abstract:
Objective To investigate the value of combined tumor markers CA125 and CA153 in diagnosing and effect monitoring in breast cancer.Methods Using electro-chemoluminescent immunoassay (ECLIA) method to determine and analyze the level of CA125 and CA153 in 170 patients with breast cancer,102 patients with benign breast disease,and 153 normal individuals.The levels of CA125 and CA153 were detected in 80 breast cancer patients with post-operation time 3 day,1 week,2 week and 1 month respectively.The results were analyzed by ROC curve.Results The serum levels of CA153 and CA125 in the patients with breast cancer were higher than those of normal individuals and patients with benign breast disease (P<0.05).The sensitivity,accuracy and negative predictive rate combined two tumor markers of serum CA153 and CA125 were 79.41%,87.53% and 87.13%,which had prognostic significance compared with CA153 and CA125 alone (P<0.05).The AUC of CA153 was 0.823 and it was higher than that of CA125.The AUC of two combined tumor markers of CA153 and CA125 was 0.876 and it was higher than any AUC of CA153 or CA125 alone (P<0.05).With pos-operation time passed by,the level of CA125 and CA153 declined gradually (P<0.05).Conclusion CA153 and CA125 were the correlative tumor markers of breast cancer,and CA153 was more helpful in diagnosing breast cancer.Detection of combining CA125 with CA153 was better than single tumor marker,which can raise the accuracy of diagnosing patients with breast cancer or monitoring their therapy effect post-operation.

参考文献/References:

[1]Brooks M.Breast cancer screening and biomarkers［J］.Methods Mol Biol,2009,472:307-321.
[2］Fitzgerald SP,Lamont JV,McConnell RI,et al.Development of a high-throughput automated analyzer using biochip array technology［J］.Clin Chem,2005,51(7):1165-1176.
[3］任传路，丁庆莉，蒋天如，等.微阵列酶联免疫法检测多项肿瘤标志物诊断原发性肝癌的临床价值［J］.国际检验医学杂志，2012,33（24）：2967-2968. 　
[4］郭旭霞，段满乐,杜肖刚,等.蛋白芯片技术检测肿瘤标志物及临床应用［J］.临床检验杂志，2004，22(3):224.
[5］Harris L,Fritsche H,Mennel R,et al.American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer［J］.J Clin Oncol,2007,25(33):5287-5312.
[6］王景萍,洪锡田,盛家和.联合检测血清糖类抗原153、糖类抗原125、癌胚抗原在乳腺癌肿的诊断价值探讨［J］.河南医学研究，2007，16(3):243-245.
[7］邱志远,许文林,奚 艳,等.蛋白芯片技术检测肿瘤标志物对乳腺癌的诊断价值［J］.实用癌症杂志,2009,24(5)：486-490.
[8］Uehara M,Kinoshita T,Hojo T,et al.Long-term prognostic study of carcinoembryonic antigen(CEA) and carbohydrate antigen 15-3(CA 15-3) in breast cancer［J］.Int J Clin Oncol，2008,13(5)：447-451
[9］Topalak O,Saygili U,Soyturk M,et al.Serum,pleural effusion,and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases:a comparative study［J］.Gynecol Oncol，2002,85(1):108-113.
[10］高 寒,姜 军,杨新华,等.5 种血清标志物的不同组合对提高乳腺癌诊断的意义［J］.第三军医大学学报,2007,29(12):1255-1257.
[11］牛 华，訾春莲，王建琼，等.ROC曲线软件在处理不同类型资料中的应用探讨［J］.中国循证医学杂志，2004，4(2):132-135.
[12］邵惠江，高 纯，公艳蕾，等.肿瘤标志物联合检测在乳腺癌诊断中的价值［J］.中国现代医学杂志，2011，21（30）：3772-3776.
[13］景 娜,韩存芝,王玉荆，等.四项肿瘤标志物检测在乳腺癌术后诊断及治疗中的价值［J］.中国医疗前沿，2012,7（3）：8-9.

相似文献/References:

[1]蒋 静,程珠玲.乳腺肿瘤患者心理护理的对策[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):553.
[2]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(05):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
[3]朱成宾,潘玉琴,何帮顺.微小RNA多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
　ZHU Cheng-bin,PAN Yu-qin,HE Bang-shun..Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
[4]刘 彧,童清平,连 娟,等.乳腺癌弹性超声特征与分子生物学指标的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
　LIU Yu,TONG Qing-ping,LIAN Juan,et al.Relationship between ultrasonic elastography features and ER， PR， Her-2 and Ki67 expression in molecular biology of breast[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
[5]陈涛,王璇,程凯,等.CD47在乳腺癌及癌旁组织中的表达及其意义[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
　CHEN Tao,WANG Xuan,CHENG Kai,et al.Expression and significance of CD47 in breast cancer and pericancerous tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(05):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
[6]陈雨秋,周国华,顾军.半乳糖凝集素3与乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
　CHEN Yu-qiu,ZHOU Guo-hua,GU Jun.Research progress of galectin-3 and breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(05):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
[7]地里呼玛尔·吐鲁洪,李欣芳,王少华.HR+/HER2-乳腺癌内分泌治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
　Dilihumaer Tuluhong,LI Xin-fang,WANG Shao-hua.The trend of endocrine therapeutic approach in HR+/HER2-breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(05):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
[8]何小芳,周敏,熊朝月,等.乳腺癌超声征象及其术后复发的危险因素分析[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
　HE Xiao-fang,ZHOU Min,XIONG Chao-yue,et al.Ultrasonicsigns of breast cancer and analysis of risk factors for postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(05):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
[9]吴勤研,蓝晓红,吴波,等.基于生物信息技术分析人参皂苷防治乳腺癌的作用机制[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
　WU Qin-yan,LAN Xiao-hong,WU Bo,et al.Analysis of the mechanism of action of ginsenosides in preventing and treating breast cancer based on bioinformatics technology[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(05):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
[10]林慧,陈佳菁,郭志锋,等.miR-9-5p在乳腺癌组织中的表达与生物信息学分析[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):23.[doi:10.3969/j.issn.1672-271X.2023.01.005]
　LIN Hui,CHEN Jiajing,GUO Zhifeng,et al.Expression and bioinformatic analysis of miR-9-5p in breast cancer tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(05):23.[doi:10.3969/j.issn.1672-271X.2023.01.005]

备注/Memo

备注/Memo:
南京军区科技攻关基金（07M016）
更新日期/Last Update: 2013-09-20